New Report Now Available!
Exclusive Data You Can't Get Anywhere Else
Biomedtracker, Amplion, and BIO are releasing the largest study ever on clinical development success rates. This report examines success rates across ~10,000 clinical program transitions by therapeutic area as well as three unique categories: rare diseases, chronic high prevalence diseases, and programs utilizing selection biomarkers. The results show dramatic differences between disease groups and modalities.
Some Key Findings:
- Programs that utilized selection biomarkers had higher success rates at each phase of development vs. the overall dataset.
- Chronic diseases with high populations had a lower Likelihood of Approval (LOA) from Phase I vs. the overall dataset.
- Rare disease programs had higher a Likelihood of Approval (LOA) from Phase I vs. the overall dataset
- Hematology had the highest LOA from Phase I, and Oncology had the lowest.
SIGN-UP TODAY TO RECEIVE THE REPORT BY EMAIL
